309 related articles for article (PubMed ID: 12544978)
1. Endotoxin as a drug target.
Opal SM; Glück T
Crit Care Med; 2003 Jan; 31(1 Suppl):S57-64. PubMed ID: 12544978
[TBL] [Abstract][Full Text] [Related]
2. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis.
Opal SM
Int J Med Microbiol; 2007 Sep; 297(5):365-77. PubMed ID: 17452016
[TBL] [Abstract][Full Text] [Related]
3. Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.
Opal SM; Yu RL
Drugs; 1998 Apr; 55(4):497-508. PubMed ID: 9561340
[TBL] [Abstract][Full Text] [Related]
4. Antiendotoxin therapies for septic shock.
Corriveau CC; Danner RL
Infect Agents Dis; 1993 Feb; 2(1):44-52. PubMed ID: 8162353
[TBL] [Abstract][Full Text] [Related]
5. Endotoxin as a therapeutic target in septic shock.
Corriveau CC; Danner RL
Infect Agents Dis; 1993 Feb; 2(1):35-43. PubMed ID: 8162352
[TBL] [Abstract][Full Text] [Related]
6. Circulating endotoxin and antiendotoxin antibodies during severe sepsis and septic shock.
Maury E; Blanchard HS; Chauvin P; Guglielminotti J; Alzieu M; Guidet B; Offenstadt G
J Crit Care; 2003 Jun; 18(2):115-20. PubMed ID: 12800122
[TBL] [Abstract][Full Text] [Related]
7. Endotoxins and other sepsis triggers.
Opal SM
Contrib Nephrol; 2010; 167():14-24. PubMed ID: 20519895
[TBL] [Abstract][Full Text] [Related]
8. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis.
Natanson C; Hoffman WD; Suffredini AF; Eichacker PQ; Danner RL
Ann Intern Med; 1994 May; 120(9):771-83. PubMed ID: 8147551
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory therapies in sepsis and septic shock.
Freeman BD; Natanson C
Expert Opin Investig Drugs; 2000 Jul; 9(7):1651-63. PubMed ID: 11060768
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies for sepsis: antiendotoxin therapies.
Manocha S; Feinstein D; Kumar A; Kumar A
Expert Opin Investig Drugs; 2002 Dec; 11(12):1795-812. PubMed ID: 12457439
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic effects of endotoxin.
Zivot JB; Hoffman WD
New Horiz; 1995 May; 3(2):267-75. PubMed ID: 7583168
[TBL] [Abstract][Full Text] [Related]
12. Current prospects for the treatment of clinical sepsis.
Suffredini AF
Crit Care Med; 1994 Jul; 22(7):S12-8. PubMed ID: 8026188
[TBL] [Abstract][Full Text] [Related]
13. Sepsis and septic shock.
Zanetti G; Baumgartner JD; Glauser MP
Schweiz Med Wochenschr; 1997 Mar; 127(12):489-99. PubMed ID: 9106949
[TBL] [Abstract][Full Text] [Related]
14. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
Calandra T; Baumgartner JD; Glauser MP
Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
[TBL] [Abstract][Full Text] [Related]
15. Endotoxic Septic Shock: Diagnosis and Treatment.
Foster DM; Kellum JA
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003374
[TBL] [Abstract][Full Text] [Related]
16. Immunological intervention in endotoxin shock.
Ziegler EJ
Prog Clin Biol Res; 1988; 272():319-25. PubMed ID: 3293079
[No Abstract] [Full Text] [Related]
17. Antiendotoxin therapy in sepsis.
Colletti RC; Dew RB; Goulart AE
Crit Care Nurs Clin North Am; 1993 Jun; 5(2):345-54. PubMed ID: 8398040
[TBL] [Abstract][Full Text] [Related]
18. Current treatment of sepsis and endotoxaemia.
Periti P
Expert Opin Pharmacother; 2000 Sep; 1(6):1203-17. PubMed ID: 11249488
[TBL] [Abstract][Full Text] [Related]
19. Treatment of sepsis: past and future avenues.
Baumgartner JD; Calandra T
Drugs; 1999 Feb; 57(2):127-32. PubMed ID: 10188756
[TBL] [Abstract][Full Text] [Related]
20. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Barriere SL; Guglielmo BJ
Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
